Up to €1,300 savings end in:
- 00Days
- 00Hrs
- 00Mins
- 00Secs
March 23–25, 2026
FIL (Feira Internacional de Lisboa), Lisbon, PortugalMarch 31 – April 1, 2026 | Digital Partnering Rafiq HasanCEO at Complement TherapeuticsSpeaker
Profile
Rafiq has a proven record of success in the global pharmaceutical industry and is currently CEO of Complement Therapeutics, which focuses on developing next generation complement medicines including an AAV gene therapy for Geographic Atrophy. In addition to his role at Complement, Rafiq holds Board and advisory roles at Exonate and BioGeneration Ventures. Previous leadership roles within the ophthalmology sector have included Senior Vice President and Global Head of Ophthalmology at Bayer, where he oversaw the launch of Eylea® for five indications within three years, and from launch to >$2.5 billion in five years.
Agenda Sessions
Sailing with clarity into the future of ophthalmology
, 15:30View Session